The UK and US have reached a important bilateral deal that will ensure zero levies on UK medicine exports entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on medicines through the NHS. This pledge ensures that import taxes on these crucial goods will remain at nothing for a timeframe of 36 months.
This agreement comes after recent statements to hike import taxes on branded pharmaceutical products, with potential rates discussed reaching double the cost.
"This arrangement with the UK strengthens the global environment for innovative medicines and brings much-needed equity to American-British pharmaceutical trade," a release said.
Commercial Impact
Medicines are one of the the United Kingdom's biggest export categories to the US, which is easily the largest destination for leading companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months prior to last September, the UK sold medicines valued at billions to the US. This figure represented 17.4% of total UK exports in that period.
"This guarantee safeguards work, increases funding and sets the stage for the UK to emerge as a global hub for life sciences," a minister commented.
Key UK Commitments
The deal involves several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to double total public funding on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Industry Background
The deal comes amid a ongoing dispute between the drug companies and the ministers over spending levels and approval rates.
These tensions were heightened by claims that American consumers were paying several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while major expansions have been directed toward American operations.
One official stated that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a share of its overall budget over the past decade.
